Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
Ibuprofen
Mylan IRE Healthcare Limited
M01AE; M01AE01
Ibuprofen
400 milligram(s)
Effervescent granules
Product not subject to medical prescription
Propionic acid derivatives; ibuprofen
Not marketed
2013-01-18
PACKAGE LEAFLET: INFORMATION FOR THE USER BRUFEN 400 MG EFFERVESCENT GRANULES ibuprofen READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 3 days with fever and 5 days with pain. WHAT IS IN THIS LEAFLET 1. What Brufen is and what it is used for 2. What you need to know before you take Brufen 3. How to take Brufen 4. Possible side effects 5. How to store Brufen 6. Contents of the pack and other information 1. WHAT BRUFEN IS AND WHAT IT IS USED FOR Brufen belongs to a group of medicines called ‘non-steroidal anti-inflammatory drugs’ or NSAIDs. One sachet of medicine contains 400 mg of ibuprofen. This medicine is for short-term use in adults and adolescents over 12 years (40 kg and above) to relieve mild to moderate pain such as headache and toothache , to relieve period pain to reduce fever (high temperature) 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BRUFEN DO NOT GIVE/TAKE BRUFEN: to children younger than 12 years of age if you are allergic to ibuprofen or any of the other ingredients of this medicine (listed in section 6) if you have ever had an allergic reaction to ibuprofen, acetylsalicylic acid or other NSAIDs - the signs include a reddening or rash of the skin, swollen face or lips, runny nose, wheezing or shortness of breath if you have (or have had two or more episodes of) a stomach/duodenal ulcer (peptic ulcer) or bleeding if you have ever had bleeding or a tear in your stomach or gut when taking NSAIDs if you have severe liver or kidney problems Perskaitykite visą dokumentą
Health Products Regulatory Authority 19 November 2020 CRN00C1GJ Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Brufen 400 mg effervescent Granules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 400 mg ibuprofen. Excipients with known effect One sachet also contains 2222 mg sucrose and 131 mg sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Effervescent granules. White granules, with orange flavour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In adults and adolescents over 12 years (≥40 kg) - Acute mild to moderate pain, such as headache and dental pain - Primary dysmenorrhoea. - Fever 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The ibuprofen dose depends on the patient’s age and body weight. The maximum single daily dose for adults and adolescents should not exceed 400 mg of ibuprofen. _Adults and adolescents older than 12 years (≥40 kg)_ 400 mg given as a single dose or up to 3 times a day with an interval of 4 to 6 hours. More than 400 mg at a time does not give a better analgesic effect. The maximum daily dose should not exceed 1200 mg. _Adolescents_ If in adolescents this medicinal product is required for more than 3 days or if symptoms worsen a doctor should be consulted _Adults_ The patient should consult a doctor if symptoms worsen, or persist for more than 3 days in case of fever and 5 days in case of pain. _Paediatric population_ Brufen400 mg effervescent Granules are not suitable for use in children under 12 years. Other more appropriate ibuprofen formulations are available for this population. Health Products Regulatory Authority 19 November 2020 CRN00C1GJ Page 2 of 13 _Elderly population_ NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events (see sections 4.4 and 4.8). If treatment is considered necessary, the Perskaitykite visą dokumentą